BPH Pharmacology: Alpha-1 Blockers and 5-Alpha-Reductase Inhibitors

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/130

encourage image

There's no tags or description

Looks like no tags are added yet.

131 Terms

1
New cards

Nonselective alpha-1 blockers (generic/trade)

Doxazosin (Cardura); prazosin (Minipress); terazosin (Hytrin)

2
New cards

Selective alpha-1 blockers (generic/trade)

Alfuzosin (Uroxatral); tamsulosin (Flomax)

3
New cards

Doxazosin (Cardura) dose

PO; 1-8 mg daily

4
New cards

Prazosin (Minipress) dose

PO; 0.5-1 mg twice daily

5
New cards

Terazosin (Hytrin) dose

PO; 1-20 mg at night

6
New cards

Alfuzosin (Uroxatral) dose

PO; 10 mg daily

7
New cards

Tamsulosin (Flomax) dose

PO; 0.4 mg daily

8
New cards

Alpha-1 blockers: mechanism of action

Block alpha-adrenergic stimulation → relax prostatic smooth muscle

9
New cards

Alpha-1 blockers: onset of symptom relief

Almost immediate

10
New cards

Alpha-1 blockers: time to max effect

Several days to a couple of weeks

11
New cards

Alpha-1 blockers: after stopping the drug

Effect reverses soon after discontinuation

12
New cards

Alpha-1 blockers: absorption

Well absorbed orally; tamsulosin absorbed slowly

13
New cards

Alpha-1 blockers: distribution

Widely distributed throughout the body

14
New cards

Alpha-1 blockers: metabolism

Extensively metabolized in the liver

15
New cards

Alpha-1 blockers: excretion

Feces and urine

16
New cards

Alpha-1 blockers used for BPH

All: doxazosin, prazosin, terazosin, tamsulosin, alfuzosin

17
New cards

Alpha-1 blockers also used for hypertension

Doxazosin, prazosin, terazosin

18
New cards

Alpha-1 blocker used for nightmares

Prazosin

19
New cards

Alpha-1 blockers: CV adverse reaction

Orthostatic hypotension

20
New cards

Alpha-1 blockers: EENT adverse reaction

Rhinitis

21
New cards

Alpha-1 blockers: endocrine adverse reactions

Decreased libido; ejaculation failure

22
New cards

Alpha-1 blockers: GI adverse reactions

Diarrhea; nausea; stomach discomfort

23
New cards

Alpha-1 blockers: MSK adverse reactions

Muscle pain; back pain

24
New cards

Alpha-1 blockers: neuro adverse reactions

Headache; dizziness; fatigue

25
New cards

Alpha-1 blockers: interactions

Any BP-lowering drug, including PDE5 inhibitors and all antihypertensives

26
New cards

Alpha-1 blockers: contraindications

Hypersensitivity; concurrent use with any PDE5 inhibitor

27
New cards

Alpha-1 blockers: when to give the first dose

In clinic or at bedtime (first-dose reaction risk)

28
New cards

Alpha-1 blockers: how to minimize first-dose orthostatic hypotension

Start low; increase dose at 2-week intervals

29
New cards

Alpha-1 blockers: patient education - orthostasis

Caution about orthostatic hypotension, especially getting out of bed at night

30
New cards

Alpha-1 blockers: patient education - side effects over time

Often fade with continued use; may return if therapy is stopped and restarted

31
New cards

5-alpha reductase inhibitors (generic/trade)

Dutasteride (Avodart); finasteride (Proscar)

32
New cards

Dutasteride (Avodart) dose

Oral; 0.5 mg daily

33
New cards

Finasteride (Proscar) dose for BPH

Oral; 5 mg daily for a minimum of 6 months

34
New cards

Hormone that stimulates prostate growth

Dihydrotestosterone (DHT)

35
New cards

5-ARIs: mechanism of action

Competitively inhibit type 2 5-alpha reductase → blocks testosterone → DHT conversion in prostate

36
New cards

Blocking DHT decreases which 2 conditions?

Benign prostatic hyperplasia; androgenetic alopecia

37
New cards

5-ARIs: absorption

Well absorbed

38
New cards

5-ARIs: distribution

Widely distributed; 90% protein-bound

39
New cards

5-ARIs: metabolism

Mainly liver (40-50%) to active metabolites

40
New cards

5-ARIs: excretion

More than half in feces; rest in urine

41
New cards

5-ARIs: clinical uses

BPH; male pattern baldness; PCOS; prostate cancer; male-to-female transgender hormone therapy

42
New cards

5-ARIs: derm adverse reaction

Cutaneous hypersensitivity

43
New cards

5-ARIs: endocrine adverse reactions

Impotence/ED; decreased libido; gynecomastia

44
New cards

5-ARIs: GU adverse reaction / lab effect

Decreased PSA, even if prostate cancer is present

45
New cards

5-ARIs: interactions

CYP3A4 inhibitors (ketoconazole) or inducers (St. John's wort)

46
New cards

5-ARIs: contraindications

Hypersensitivity; serious skin reaction to another 5-ARI; pediatric patients; pregnancy

47
New cards

Finasteride: teratogenic effect

Abnormal genitalia in male offspring

48
New cards

Finasteride: handling precaution

Should not be handled by women who are or may become pregnant

49
New cards

5-ARIs: blood donation

Avoid donating blood for at least 6 months after the drug

50
New cards

5-ARIs: combination therapy trend

Combined with an alpha blocker is becoming more common

51
New cards

5-ARIs: effect of daily treatment

Lower serum DHT → suppress prostate growth, decrease volume up to 30%, increase urine flow

52
New cards

5-ARIs: max decrease in prostate volume

Up to 30%

53
New cards

Why is the 5-ARI PSA drop a concern?

PSA is used to screen for prostate cancer

54
New cards

5-ARIs: patient education - time to relief

3-6 months of therapy may be needed

55
New cards

Testosterone deficiency: definition

Endocrine deficiency state with decreased testosterone levels

56
New cards

Hypogonadism: definition

Low serum testosterone with associated symptoms

57
New cards

Hypogonadism: mood/energy/cognition symptoms

Depressed mood; diminished energy; fatigue; impaired cognition

58
New cards

Hypogonadism: body composition symptoms

Decreased muscle strength and bulk; increased fat mass; decreased bone density

59
New cards

Hypogonadism: metabolic/blood findings

Anemia; increased insulin resistance

60
New cards

Hypogonadism: sexual symptoms

Decreased libido; ED

61
New cards

Total testosterone measures

Free + bound testosterone

62
New cards

Primary vs. secondary testosterone deficiency

Primary = gonadal/testicular failure; secondary = hypothalamic-pituitary failure

63
New cards

Testosterone deficiency: labs to order

Total testosterone; free testosterone; SHBG-bound testosterone; LH; FSH

64
New cards

Low testosterone + low or normal LH/FSH suggests

Hypothalamic-pituitary problem; further workup (MRI)

65
New cards

Testosterone deficiency: why order CBC and fasting glucose?

Deficiency can cause anemia and insulin resistance

66
New cards

Testosterone deficiency: treatment

Exogenous testosterone

67
New cards

Methyltestosterone (Android)

PO; 10-50 mg daily

68
New cards

Fluoxymesterone (Halotestin)

PO; 5-20 mg daily

69
New cards

Testosterone buccal (Striant)

Buccal; 30 mg 2 times/day

70
New cards

Testosterone patch (Androderm)

Nonscrotal skin; 2.5-5 mg/24 hr daily

71
New cards

Testosterone cypionate (Depo-Testosterone)

IM; 50-400 mg every 2-4 weeks

72
New cards

Testosterone enanthate (Delatestryl)

IM; 50-400 mg every 2-4 weeks

73
New cards

Testosterone 1% gel (AndroGel)

Nonscrotal skin; 5 g daily

74
New cards

Testosterone pellets (Testopel)

SC; 150-450 mg every 3-6 months

75
New cards

Exogenous testosterone: pharmacokinetics vary by

Ester type and route of administration

76
New cards

Testosterone: absorption

Complete when given IM

77
New cards

Testosterone: distribution

~98% protein-bound to sex hormone-binding globulin (SHBG)

78
New cards

Testosterone: metabolism

First-pass hepatic metabolism; active metabolites

79
New cards

Testosterone: excretion

90% urine; rest feces

80
New cards

Testosterone: clinical uses

Delayed male puberty; male hypogonadism (replacement); male osteoporosis

81
New cards

Testosterone: CV adverse reactions

MI; CVA; DVT/PE

82
New cards

Testosterone: derm adverse reactions

Acne; hirsutism; male pattern baldness

83
New cards

Testosterone: endocrine adverse reactions

Breast soreness; gynecomastia

84
New cards

Testosterone: GI adverse reaction

Nausea

85
New cards

Testosterone: GU adverse reactions

Priapism; testicular atrophy; oligozoospermia

86
New cards

Testosterone: heme/hepatic adverse reactions

erythrocytosis; polycythemia

87
New cards

Testosterone: neuro adverse reactions

Aggression; amnesia; anxiety; depression; nervousness; sleeplessness

88
New cards

Testosterone: drug interaction

Oral anticoagulants (warfarin): increased anticoagulant (hypothrombotic) effect

89
New cards

Testosterone: contraindications

Hypersensitivity; male breast cancer; prostate cancer; pregnancy

90
New cards

Testosterone: H&P monitoring schedule

Every 3-4 months for 1 year, then annually

91
New cards

Testosterone: poor or no response at 3-4 months

Increase dose, or stop if at maximum dose

92
New cards

Testosterone: lab monitoring

Lipids; PSA; hematocrit

93
New cards

IM testosterone: when to draw levels

Just before the next IM dose, until stable

94
New cards

Oral testosterone: extra monitoring

LFTs every 3-6 months

95
New cards

Testosterone: cancer concern

Suspected stimulant of breast and prostate cancer; keep up screening

96
New cards

Testosterone: who needs erythropoiesis monitoring?

Smokers; vascular disease; history of polycythemia

97
New cards

Testosterone: significant hematocrit rise

Discontinue medication

98
New cards

Testosterone: controlled substance schedule

Schedule III (all forms)

99
New cards

Testosterone: patient education - expected results

Many symptoms don't respond; age and physical condition may limit results

100
New cards

Testosterone: patient education - pregnant women

Pregnant or childbearing-age women should avoid contact with gels/patches; fetal harm possible